Showing results (241-250 of 277) with videos related to
Sort By:
Pageof 28
British Journal of Haematology|September 27, 2024
Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysisJing Liu, Fenghua Gao, Tingting Zhang, et al.Theranostics|March 23, 2021
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphomaQingzhu Jia, Diyuan Qin, Feng He, et al.Frontiers in Medicine|February 19, 2021
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical TrialWeiping Liu, Yufu Li, Quanshun Wang, et al.Nature Communications|January 9, 2020
The Mouse Gut Microbial Biobank expands the coverage of cultured bacteriaChang Liu, Nan Zhou, Meng-Xuan Du, et al.Experimental Hematology & Oncology|October 16, 2023
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignanciesYuqin Song, Shang-Ju Wu, Zhixiang Shen, et al.Journal of Hematology & Oncology|February 16, 2021
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyHuiqiang Huang, Jun Zhu, Ming Yao, et al.Frontiers in Oncology|March 15, 2021
Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative GroupWeiping Liu, Yong Yang, Shunan Qi, et al.Biomarker Research|February 7, 2023
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter studyJie Zha, Qinwei Chen, Jingjing Ye, et al.Journal of Hematology & Oncology|September 29, 2022
Evidence-based expert consensus on the management of primary central nervous system lymphoma in ChinaTong Chen, Yuanbo Liu, Yang Wang, et al.European Journal of Cancer (Oxford, England : 1990)|August 31, 2021
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II studyNingjing Lin, Mingzhi Zhang, Hai Bai, et al.Pageof 28